These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19350606)

  • 1. Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors.
    Castaño T; Wang H; Campillo NE; Ballester S; González-García C; Hernández J; Pérez C; Cuenca J; Pérez-Castillo A; Martínez A; Huertas O; Gelpí JL; Luque FJ; Ke H; Gil C
    ChemMedChem; 2009 May; 4(5):866-76. PubMed ID: 19350606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7.
    Sharma H; Lather V; Grewal AS; Pandita D
    Curr Comput Aided Drug Des; 2019; 15(3):225-234. PubMed ID: 30280674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors.
    Sánchez AI; Martínez-Barrasa V; Burgos C; Vaquero JJ; Alvarez-Builla J; Terricabras E; Segarra V
    Bioorg Med Chem; 2013 Apr; 21(8):2370-2378. PubMed ID: 23454131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions.
    Szczypka M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.
    Guo J; Watson A; Kempson J; Carlsen M; Barbosa J; Stebbins K; Lee D; Dodd J; Nadler SG; McKinnon M; Barrish J; Pitts WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1935-8. PubMed ID: 19272774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
    Chłoń-Rzepa G; Jankowska A; Ślusarczyk M; Świerczek A; Pociecha K; Wyska E; Bucki A; Gawalska A; Kołaczkowski M; Pawłowski M
    Eur J Med Chem; 2018 Feb; 146():381-394. PubMed ID: 29407965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.
    González-García C; Bravo B; Ballester A; Gómez-Pérez R; Eguiluz C; Redondo M; Martínez A; Gil C; Ballester S
    Br J Pharmacol; 2013 Oct; 170(3):602-13. PubMed ID: 23869659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.
    Zhang L; Murray F; Zahno A; Kanter JR; Chou D; Suda R; Fenlon M; Rassenti L; Cottam H; Kipps TJ; Insel PA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19532-7. PubMed ID: 19033455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research.
    Jankowska A; Swierczek A; Chlon-Rzepa G; Pawlowski M; Wyska E
    Curr Med Chem; 2017; 24(7):673-700. PubMed ID: 28093982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
    Wang H; Liu Y; Chen Y; Robinson H; Ke H
    J Biol Chem; 2005 Sep; 280(35):30949-55. PubMed ID: 15994308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold.
    Sánchez AI; Meneses R; Mínguez JM; Núñez A; Castillo RR; Filace F; Burgos C; Vaquero JJ; Álvarez-Builla J; Cortés-Cabrera A; Gago F; Terricabras E; Segarra V
    Org Biomol Chem; 2014 Jun; 12(24):4233-42. PubMed ID: 24838636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New classes of PDE7 inhibitors identified by a fission yeast-based HTS.
    Alaamery MA; Wyman AR; Ivey FD; Allain C; Demirbas D; Wang L; Ceyhan O; Hoffman CS
    J Biomol Screen; 2010 Apr; 15(4):359-67. PubMed ID: 20228279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.
    Endo Y; Kawai K; Asano T; Amano S; Asanuma Y; Sawada K; Ogura K; Nagata N; Ueo N; Takahashi N; Sonoda Y; Kamei N
    Bioorg Med Chem Lett; 2015 Feb; 25(3):649-53. PubMed ID: 25529739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
    García AM; Brea J; Morales-García JA; Perez DI; González A; Alonso-Gil S; Gracia-Rubio I; Ros-Simó C; Conde S; Cadavid MI; Loza MI; Perez-Castillo A; Valverde O; Martinez A; Gil C
    J Med Chem; 2014 Oct; 57(20):8590-607. PubMed ID: 25264825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases.
    Martinez A; Gil C
    Expert Opin Ther Pat; 2014 Dec; 24(12):1311-21. PubMed ID: 25284693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
    Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple cAMP Phosphodiesterases Act Together to Prevent Premature Oocyte Meiosis and Ovulation.
    Vigone G; Shuhaibar LC; Egbert JR; Uliasz TF; Movsesian MA; Jaffe LA
    Endocrinology; 2018 May; 159(5):2142-2152. PubMed ID: 29608743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders.
    Safavi M; Baeeri M; Abdollahi M
    Expert Opin Drug Discov; 2013 Jun; 8(6):733-51. PubMed ID: 23570245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.